title: Metabolism of short-chain ceramide by human cancer cells--implications for therapeutic approaches.
abstract: Due to recent use of short-chain ceramides in preclinical studies, we characterized C6-ceramide metabolism in cancer cell lines and assessed metabolic junctures for enhancing efficacy. MDA-MB-231 breast cancer cells decreased the amount of C6-ceramide metabolized to C6-sphingomyelin (C6-SM) and increased the amount metabolized to C6-glucosylceramide (C6-GC) in response to increasing concentrations. A similar trend was seen in DU-145 (prostate cancer), PANC-1 (pancreatic cancer), and LoVo (colorectal cancer) cells. KG-1 leukemia cells favored C6-SM synthesis at low (0.6muM) and high-dose (12muM) C6-ceramide. Partnering C6-ceramide with tamoxifen, a P-glycoprotein antagonist that impedes ceramide glycosylation, was an effective regimen for enhancing cytotoxicity in cells. Experiments to assess the mechanism of cell death using KG-1 cells showed that tamoxifen inhibited synthesis of C6-GC and C6-SM from C6-ceramide by 80% and 50%, respectively, which was accompanied by enhanced apoptosis. Radiolabeling of KG-1 cells with [(3)H]palmitic acid produced a 2-fold increase in (3)H-long-chain ceramides when unlabeled C6-ceramide was added and a 9-fold increase when C6-ceramide and tamoxifen were added. The increase in (3)H-palmitate radiolabeling of long-chain ceramides was blocked by inclusion of a ceramide synthase inhibitor; however, inhibiting synthesis of long-chain ceramide did not rescue cells. These studies show that tamoxifen enhances the apoptotic effects of C6-ceramide. The proposed mechanism involves blocking short-chain ceramide anabolism to favor hydrolysis and generation of sphingosine. We propose that use of tamoxifen and other P-glycoprotein antagonists can be an effective means for enhancing cytotoxic potential of short-chain ceramides in the treatment of cancer.
authors.affiliation: John Wayne Cancer Institute at Saint John's Health Center, Department of Experimental Therapeutics, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA.
authors.forename: Jacqueline V
authors.initials: JV
authors.lastname: Chapman
authors.forename: Valérie
authors.initials: V
authors.lastname: Gouazé-Andersson
authors.forename: Maria C
authors.initials: MC
authors.lastname: Messner
authors.forename: Margaret
authors.initials: M
authors.lastname: Flowers
authors.forename: Ramin
authors.initials: R
authors.lastname: Karimi
authors.forename: Mark
authors.initials: M
authors.lastname: Kester
authors.forename: Brian M
authors.initials: BM
authors.lastname: Barth
authors.forename: Xin
authors.initials: X
authors.lastname: Liu
authors.forename: Yong-Yu
authors.initials: YY
authors.lastname: Liu
authors.forename: Armando E
authors.initials: AE
authors.lastname: Giuliano
authors.forename: Myles C
authors.initials: MC
authors.lastname: Cabot
mesh_terms: D045744:Cell Line, Tumor; D002470:Cell Survival / Q000502:physiology; D002518:Ceramides / Q000737:chemistry / Q000378:metabolism* / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D013629:Tamoxifen / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use
chemical_list: D002518:Ceramides; C101954:N-caproylsphingosine; D013629:Tamoxifen
references.citation: Urology. 2003 May;61(5):1047-52
references.pmid: 12736045
references.citation: Mol Cancer Ther. 2004 May;3(5):633-9
references.pmid: 15141021
references.citation: Int J Oncol. 2000 Dec;17(6):1077-86
references.pmid: 11078791
references.citation: J Biochem. 1992 Feb;111(2):191-6
references.pmid: 1533217
references.citation: FASEB J. 2008 Jul;22(7):2541-51
references.pmid: 18245173
references.citation: Cell. 1996 Nov 1;87(3):507-17
references.pmid: 8898203
references.citation: Curr Protein Pept Sci. 2002 Dec;3(6):653-70
references.pmid: 12470219
references.citation: Mol Cancer Ther. 2008 Sep;7(9):2967-76
references.pmid: 18790777
references.citation: Curr Drug Targets. 2008 Aug;9(8):674-82
references.pmid: 18691014
references.citation: J Natl Cancer Inst. 2001 Mar 7;93(5):347-57
references.pmid: 11238696
references.citation: Cancer Res. 2005 May 1;65(9):3861-7
references.pmid: 15867385
references.citation: Mini Rev Med Chem. 2007 Oct;7(10):984-90
references.pmid: 17979800
references.citation: J Biol Chem. 1996 Aug 9;271(32):19530-6
references.pmid: 8702646
references.citation: Int J Cancer. 2000 Jul 15;87(2):172-8
references.pmid: 10861470
references.citation: Biochim Biophys Acta. 2002 Dec 30;1585(2-3):172-8
references.pmid: 12531551
references.citation: J Biol Chem. 2000 Mar 10;275(10):7138-43
references.pmid: 10702281
references.citation: Eur J Biochem. 1992 Dec 15;210(3):765-73
references.pmid: 1483461
references.citation: J Biol Chem. 2002 Apr 12;277(15):12960-9
references.pmid: 11815611
references.citation: Exp Mol Pathol. 2007 Feb;82(1):1-11
references.pmid: 16624283
references.citation: Biochim Biophys Acta. 2003 May 2;1612(1):98-106
references.pmid: 12729935
references.citation: Clin Cancer Res. 2008 May 15;14(10):3193-203
references.pmid: 18483388
references.citation: Anticancer Res. 1998 Jan-Feb;18(1B):475-80
references.pmid: 9568165
references.citation: Biochem J. 2005 Jul 15;389(Pt 2):517-26
references.pmid: 15799713
references.citation: J Biol Chem. 1997 Jan 17;272(3):1682-7
references.pmid: 8999846
references.citation: J Biol Chem. 1999 Jan 8;274(2):1140-6
references.pmid: 9873062
references.citation: Exp Cell Res. 1999 Nov 1;252(2):464-70
references.pmid: 10527636
references.citation: Curr Drug Targets. 2008 Aug;9(8):662-73
references.pmid: 18691013
references.citation: Biochem J. 2002 May 1;363(Pt 3):777-84
references.pmid: 11964179
references.citation: PLoS One. 2009 Sep 09;4(9):e6938
references.pmid: 19742320
references.citation: Int J Oncol. 1999 Sep;15(3):535-40
references.pmid: 10427136
references.citation: Biochim Biophys Acta. 2000 Jun 26;1486(1):128-44
references.pmid: 10856718
references.citation: Cell Death Differ. 1998 Sep;5(9):785-91
references.pmid: 10200538
references.citation: FEBS Lett. 1996 Sep 30;394(2):129-31
references.pmid: 8843149
references.citation: Clin Cancer Res. 2000 Mar;6(3):942-8
references.pmid: 10741719
references.citation: Biochim Biophys Acta. 2006 Dec;1758(12):2096-103
references.pmid: 17010304
references.citation: Drug Metab Dispos. 2008 Aug;36(8):1709-15
references.pmid: 18490436
references.citation: Subcell Biochem. 2008;49:413-40
references.pmid: 18751921
references.citation: J Biochem. 2006 Feb;139(2):255-62
references.pmid: 16452313
references.citation: Biochem Pharmacol. 2000 Apr 1;59(7):821-9
references.pmid: 10718340
references.citation: Clin Cancer Res. 2008 Jun 1;14(11):3571-81
references.pmid: 18519791